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Abstract
Background: Small-bowel angioectasias are frequently diagnosed with capsule endoscopy (CE) or balloon endoscopy
however, major predictors have not been defined and the indications for endoscopic treatment have not
been standardized. The aim of this study was to evaluate the predictors and management of small-bowel
angioectasia.
Methods: Among patients with obscure gastrointestinal bleeding (OGIB) who underwent both CE and double-balloon
endoscopy at our institution, we enrolled 64 patients with small-bowel angioectasia (angioectasia group) and 97 patients
without small-bowel angioectasia (non-angioectasia group). The angioectasia group was subdivided into patients with
type 1a angioectasia (35 cases) and type 1b angioectasia (29 cases) according to the Yano-Yamamoto classification.
Patient characteristics, treatment, and outcomes were evaluated.
Results: Age (P = 0.001), cardiovascular disease (P = 0.002), and liver cirrhosis (P = 0.003) were identified as significant
predictors of small-bowel angioectasia. Multivariate logistic regression analysis identified cardiovascular disease
(odds ratio 2.86; 95 % confidence interval, 1.35–6.18) and liver cirrhosis (odds ratio 4.81; 95 % confidence interval,
1.79–14.5) as independent predictors of small-bowel angioectasia. Eleven type 1a cases without oozing were
treated conservatively, and 24 type 1a cases with oozing were treated with polidocanol injection (PDI). Re-bleeding
occurred in two type 1a cases (6 %). Seventeen type 1b cases were treated with PDI and 12 type 1b cases
were treated with PDI combined with argon plasma coagulation (APC) or clipping. Re-bleeding occurred in
five type 1b cases (17 %) that resolved after additional endoscopic hemostasis in all cases. There was one
adverse event from endoscopic treatment (1.6 %).
Conclusions: Cardiovascular disease and liver cirrhosis were significant independent major predictors of small-bowel
angioectasia. Type 1a angioectasias with oozing are indicated for PDI and type 1b angioectasias are indicated for PDI
with APC or clipping.
Background
Small-bowel vascular lesions, especially small-bowel
angioectasias, account for a large number of cases of ob-
scure gastrointestinal bleeding (OGIB) [1]. Small-bowel
bleeding accounts for 5 % of all gastrointestinal bleeding
cases [2], and vascular lesions account for 23–52 % of cases
of small-bowel bleeding [3–5]. Small-bowel angioectasias
comprise the majority of small-bowel vascular lesions and
are found in 30–40 % of OGIB cases [6]. Despite these
facts, the major predictors for small-bowel angioectasia
have not been determined.
Angioectasia is a collection of abnormal blood vessels
composed of thin tortuous capillaries without an internal
elastic membrane. Yano-Yamamoto’s [7] accepted endo-
scopic classification of small-bowel vascular lesions clas-
sifies small-bowel angioectasia as a type 1 lesion (Fig. 1).
These lesions are further subclassified, as follows: type
1a lesions are characterized by punctate erythema (<1 mm)
with or without oozing, and type 1b lesions are character-
ized by patchy erythema (2–3 mm) with or without oozing.
Fan et al. reported the use of argon plasma coagulation
(APC) for the endoscopic treatment of small-bowel
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angioectasia [8]. However, there is no consensus on the op-
timal endoscopic treatment of small-bowel angioectasia.
We analyzed patient characteristics and endoscopic
treatments for small-bowel angioectasia cases diagnosed
using both capsule endoscopy (CE) and double-balloon
endoscopy (DBE) at our institution and followed for at
least 1 year. The aim of this study was to determine the




A total of 800 patients with OGIB presented to Hiroshima
University Hospital between April 2004 and December
2013. Two hundred thirty-eight of those patients under-
went both CE and DBE. Sixty-four patients diagnosed with
small-bowel angioectasia were assigned to the angioectasia
group. Ninety-seven patients without small-bowel angioec-
tasia were assigned to the non-angioectasia group. We ex-
cluded 77 patients in whom the entire small bowel had not
been visualized. The angioectasia group was subclassified
into patients with type 1a (35 cases) and type 1b (29 cases)
angioectasias according to the Yano-Yamamoto classifica-
tion (Fig. 2). All patients underwent upper and lower
gastrointestinal endoscopies prior to CE and DBE.
The study was conducted in accordance with the Dec-
laration of Helsinki and was approved by the Institutional
Review Board of Hiroshima University Hospital. Written
informed consent was obtained from all of the patients
who participated in the study.
CE procedure
CE was performed using PillCam SB1 or PillCam SB2 cap-
sules (Given Imaging Ltd, Yokneam, Israel). The capsule
was swallowed with a dimethicone solution after an over-
night fast, without any other preparation. Patients were
allowed to drink clear liquids and eat a light meal 2 h and
4 h after swallowing the capsule, respectively. The sensor
array and recording device were removed 8 h after swal-
lowing the capsule. Images were analyzed with Rapid
Reader 6 software on a RAPID 5 or 6.5work station (soft-
ware and workstation from Given Imaging Ltd).
DBE procedure
All DBE procedures were performed using the DBE sys-
tem (FUJIFILM, Saitama, Japan) employing a FUJIFILM
EN-450 P5 or EN-450 T5-type endoscope. Per oral in-
sertion of the endoscope required that patients fast for
8–12 h, similar to the preparation for upper gastrointes-
tinal endoscopy. All rectal insertions required a prepar-
ation similar to that used for colonoscopy. Patients were
lightly sedated with pentazocine (15 mg) and midazolam
(0.05 mg/kg). We selected the oral or rectal route based
on the results of CE. If a source of bleeding was not
identified during the examination, we marked the small-
bowel mucosa with pure carbon at the most distal point.
Strategy of endoscopic treatment for small-bowel
angioectasia
Type 1a lesions without oozing were treated conserva-
tively without any endoscopic intervention. Type 1a le-
sions with oozing were treated with 1 % polidocanol
injection (PDI) in all cases. Type 1b lesions were treated
with PDI or PDI combined with APC or clipping, accord-
ing to the condition of the lesions or the endoscope used
for treatment. We analyzed the re-bleeding rate and endo-
scopic treatment related adverse events. Re-bleeding was
defined as evidence of recurrent visible gastrointestinal
bleeding (melena or hematochezia) with recent negative
upper and lower gastrointestinal endoscopies and/or a sub-
sequent decrease in the hemoglobin level by >2 g/dL from







Punctuate erythema (less than 1 mm) with or without oozing
Patchy erythema (a few mm) with or without oozing
Punctuate lesions (less than 1 mm) with pulsatile bleeding 
Pulsatile red protrusion without surrounding venous dilation 
Pulsatile red protrusion with surrounding venous dilation  
Other lesions not classified into any of the above categories
Fig. 1 Endoscopic classification of small-bowel vascular lesions (Yano-Yamamoto classification)
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bowel bleeding from lesions other than those previously
treated by endoscopic hemostasis. In addition, follow-up
CE or DBE was performed 3–6 months after endoscopic
hemostasis for all patients.
Evaluation
Patient characteristics, including age, sex, bleeding type
(overt or occult), drug use (antithrombotic and nonste-
roidal anti-inflammatory drugs), and underlying diseases
(cerebrovascular disease, cardiovascular disease, chronic
renal failure, hypertension, dyslipidemia, diabetes, and
liver cirrhosis) were recorded for the two groups. Lesion
characteristics for the type 1a and type 1b groups, in-
cluding number of lesions, location in the small-bowel,
outcomes after endoscopic treatment, and re-bleeding rate
were evaluated. In addition, we divided the type 1b group
into two groups according to the treatment methods used
(treated with PDI or treated with PDI combined with APC
or clipping). The rate of re-bleeding-free survival was cal-
culated and compared between the two groups. The entire
small bowel was divided into three parts (upper, middle,
and lower) based on CE transit times in accordance with a
previous report by Li et al [9]. The first two parts of the
small bowel were considered the jejunum, and the last
part was considered the ileum.
Statistical analysis
Comparisons were performed using the unpaired t-test for
quantitative data and the chi-squared test for categorical
data. A Yates correction or Fisher’s exact test was used
when required. All tests were two-sided, and a P-value <
0.05 was considered statistically significant. Odds ratios
(ORs) and 95 % confidence intervals (95 % CIs) were used
in the multivariate logistic regression analyses. The re-
bleeding-free interval was estimated using the Kaplan-
Meier method. The JMP10 statistical software package
(SAS Institute Inc., Cary, NC, USA) was used for all
analyses.
Results
Patient age, cardiovascular disease, and liver cirrhosis
were significantly associated with small-bowel angioecta-
sia (P = 0.001, P = 0.002, and P = 0.003, respectively)
(Table 1). On multivariate logistic regression analysis,
cardiovascular disease (OR, 2.86; 95 % CI, 1.35–6.18)
and liver cirrhosis (OR, 4.81; 95 % CI, 1.79–14.5) were
significant predictors of small-bowel angioectasia (Table 2).
In addition, a separate analysis of the type 1a and type 1b
groups revealed no differences between the two groups
(Table 3).
Eleven type 1a cases without oozing were treated con-
servatively without endoscopic intervention, and 24 type
1a cases with oozing were treated endoscopically with
PDI. Re-bleeding occurred in two cases (6 %), one was
treated conservatively and the other was treated with
PDI. The mean time to re-bleeding was 23 days, and in
both cases, bleeding occurred from lesions other than
those previously treated. One patient had bleeding from
a small-bowel arteriovenous malformation and the other
had a small-bowel Dieulafoy’s lesion. Of the type 1b cases,
17 were treated with PDI and 12 were treated with PDI
combined with APC or clipping. Re-bleeding occurred in
five cases (17 %), four who had been initially treated with
PDI, and one who had been initially treated with PDI
combined with APC (Table 4). The mean time to re-
bleeding was 123 days. Four re-bleeding cases involved
previously treated lesions, and one involved a previously
untreated lesion. Re-bleeding was controlled conservatively
Angioectasia +
OGIB* patients underwent CE** and DBE***: 238 cases
Type 1a: 35 cases Type 1b: 29 cases
Angioectasia -
Non-angioectasia Group: 97 casesAngioectasia Group: 64 cases
Excluded those whose entire 
Methods and Patients 
small 
bowel was unobserved: 77 cases
Fig. 2 Flow chart of study patients. * Obscure gastrointestinal bleeding ** Capsule endoscopy *** Double-balloon endoscopy
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with additional endoscopic hemostasis in all cases. The
Kaplan-Meier curve for post-treatment re-bleeding in type
1b angioectasias showed no statistically significant
difference between those treated with PDI alone and
those treated with PDI combined with APC or clip-
ping (P = 0.29) (Fig. 3). One adverse event (1.6 %)
occurred as a result of endoscopic treatment in a
patient who developed an ulcer after PDI. This
patient recovered with conservative treatment.
Discussion
The etiology of gastrointestinal angioectasia remains un-
clear. Regula et al. suggested that a neurohormonal abnor-
mality, in which sympathetic nerve stimulation occurs in
response to chronic hypoperfusion, leads to relaxation of
intestinal vascular smooth muscle, causing local vascular
overload, dilation, and eventually, permanent angioectasia
[10]. Junquera et al. reported that the overexpression of an-
giogenic factors, such as basic fibroblast growth factor and
vascular endothelial growth factor, seems to play a patho-
genic role in the development of angioectasia [11, 12].
In this study, cardiovascular disease and liver cirrhosis
were independent predictors of small-bowel angioectasia.
Aortic stenosis [13], chronic renal failure [14], and von
Willebrand disease [15] have all been associated with
gastrointestinal angioectasia. Hemorrhagic gastrointestinal
angioectasia associated with aortic stenosis has been re-
ported as Heyde’s syndrome [13]. In the present study,
there were four patients in the angioectasia group (6 %)
who had aortic stenosis. Additionally, portal hypertensive
enteropathy (PHE) associated with portal hypertension in
patients with liver cirrhosis has been reported to be a
major cause of gastrointestinal bleeding [16]. The endo-
scopic findings for PHE have been described as red spots,
erosions, angioectasia, villous edema, and varices. The
presumed cause is blood-flow stasis associated with portal
hypertension however, the pathogenesis remains un-
known. De Palma et al. conducted a CE-based study and
found PHE in 67 % of patients with liver cirrhosis [17].
We previously reported the use of CE to diagnose PHE,
especially in patients with Child-Pugh class B or C, ascites,
and portal hypertensive gastropathy in patients with com-
pensated liver cirrhosis and portal hypertension [18]. In
addition, previously reported major predictors of PHE
were the presence of a left gastric vein and splenorenal
shunts [19]. Therefore, we believe that patients with OGIB




Angioectasia group Non-angioectasia group P-value
(n = 64) (n = 97)
Sex
Male 39 57 n.s
Female 25 40
Age (years)
Mean ± SD 71.2 ± 13.9 63.4 ± 17.3 <0.01
Median (range) 75.5 (27–87) 66 (17–85)
< 65 18 43 <0.05
≧65 46 54
OGIB type




Yes 20 18 n.s
No 44 79
NSAIDS




Yes 6 8 n.s
No 58 89
Cardiovascular disease
Yes 27 19 <0.01
No 37 78
Chronic renal failure
Yes 6 7 n.s
No 58 90
Hypertension
Yes 38 43 n.s
No 26 54
Dyslipidemia
Yes 9 10 n.s
No 55 87
Diabetes
Yes 15 16 n.s
No 49 81
Liver cirrhosis
Yes 15 6 <0.01
No 49 91
Abbreviations: OGIB obscure gastrointestinal bleeding; NSAIDS nonsteroidal
anti-inflammatory drugs
Table 2 Multivariate logistic regression analyses of predictors of
small-bowel angioectasia
Clinical factors Odds ratio 95 % confidence interval P-value
Liver cirrhosis 4.81 1.79–14.5 0.0028
Cardiovascular disease 2.86 1.35–6.18 0.0066
Age (≧65) 1.25 0.60–2.60 0.550
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with cardiovascular disease and/or liver cirrhosis should
undergo CE and/or DBE to evaluate possible bleeding
from small-bowel angioectasia.
The clinical usefulness of CE for the evaluation of OGIB
has been previously reported [20, 21], and CE has become
the initial diagnostic choice for the evaluation of patients
with OGIB who do not require emergency hemostatic
intervention. Small-bowel angioectasias may be easily
missed by CE because of their small size; however, we have
reported increased detection rates with the use of flexible
spectral imaging color enhancement (FICE) [22, 23]. Maeda
et al. also reported that FICE 3 was useful for the differen-
tial diagnosis of red spots and angioectasia in the small-
bowel [24]. In addition, we compared the diagnostic
capability of CE and DBE to detect small-bowel lesions in
patients with OGIB who had their entire small bowel visu-
alized. The diagnostic concordance rates for CE and DBE
were high for small-bowel lesions, and when results varied,
it was due to false-negative CE results [25]. Postga et al. re-
ported that false- negative cases with CE were more typic-
ally seen with upper small-bowel lesions [26]. Detailed
observation is necessary, and repeat CE or DBE should be
performed when bleeding persists despite a previously
negative CE results in patients with OGIB.
Endoscopic injection sclerotherapy with polidocanol has
been used for endoscopic hemostasis in patients with
esophageal varices [27] and gastric ulcers with excellent
results [28]. Okano et al. reported the early and late
Table 3 Comparison of patient’s characteristics between type




Type 1a (n = 35) Type 1b (n = 29)
Sex
Male 22 17 n.s
Female 13 12
Age (years)
Mean ± SD 69.3 ± 16.4 73.5 ± 10.8 n.s
Median (range) 75 (27–87) 78 (42–86)
< 65 12 6 n.s
≧65 23 23
OGIB type




Yes 10 10 n.s
No 25 19
NSAIDS




Yes 3 3 n.s
No 32 26
Cardiovascular disease
Yes 14 13 n.s
No 21 16
Chronic renal failure
Yes 3 3 n.s
No 32 26
Hypertension
Yes 18 19 n.s
No 17 10
Dyslipidemia
Yes 4 5 n.s
No 31 24
Diabetes
Yes 7 7 n.s
No 28 22
Liver cirrhosis
Yes 8 7 n.s
No 27 22
Abbreviations: OGIB obscure gastrointestinal bleeding; NSAIDS nonsteroidal
anti-inflammatory drugs
Table 4 Comparison of lesion characteristics between type 1a
and 1b angioectasias
Lesion characteristics Angioectasia P-value
Type 1a (n = 35) Type 1b (n = 29)
Number
Single 20 18 n.s
Multiple 15 11
Localization of the small-bowel




Follow up 11 0
PDI 24 17
PDI + APC or clipping 0 12
Re-bleeding after
treatment, n (%)
2 (6 %) 5 (17 %) n.s
Present lesion 0 4
New other lesion 2 1
Days to re-bleeding 23 123
Follow-up period, mean ±
SD [months]
54 ± 30 53 ± 25 n.s
Abbreviations: PDI polidocanol injection, APC argon plasma coagulation
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hemostatic properties of polidocanol from research con-
ducted in dogs. The early hemostatic effects were the
result of pressure on the blood vessels with associated
interstitial edema and thrombosis formation in small
blood vessels, and the late hemostatic effects were due to
thrombus formation from vascular inflammation [29].
Takeuchi et al. reported that the effects of PDI were lim-
ited to the submucosal layer and that deeper penetration
and perforation after PDI did not occur [30].
Re-bleeding in patients with type 1a angioectasia was
secondary to other vascular lesions that had not been pre-
viously treated. As there is a possibility of missing small le-
sions, such as Dieulafoy’s lesions, in the small bowel, we
performed a detailed follow-up observation because of the
possibility of heterochronic multiple small-bowel vascular
lesions. In contrast, re-bleeding occurred in five patients
with type 1b (17 %), and, in four of these cases, bleeding
occurred in previously treated lesions. Fan et al. reported
that the rate of re-bleeding from previously treated small-
bowel angioectasias was about 25 % and that advanced age
was a risk factor for re-bleeding [8]. Rahmi et al. also re-
ported in a long-term follow-up study that cardiovascular
disease was an independent risk factor for re-bleeding in
patients with OGIB with small-bowel angioectasia treated
by DBE [31]. In the present study, endoscopic treatments
successfully treated type 1a angioectasias. Type 1b angioec-
tasias treated with PDI were more likely to have re-bleeding
compared to type 1b angioectasias treated with PDI com-
bined with APC or clipping, but the difference was not sta-
tistically significant, likely due to the small number of cases.
PDI combined with APC or clipping should be considered
in type 1b angioectasia because PDI alone may not be effi-
cacious. Therefore, it appears that the appropriate endo-
scopic treatment method is determined according to the
type of small-bowel angioectasia. In addition, since all re-
bleeding cases occurred within 1 year, we recommend strict
observation for 1 year after endoscopic treatment.
Our study had some limitations. First, it was a retro-
spective study, and therefore, a selection bias was inevit-
able. Second, the study included patients from a single
center only. Therefore, a large-scale, prospective study is
needed to address these limitations.
Conclusions
Cardiovascular disease and liver cirrhosis were significant
independent major predictors of small-bowel angioectasia.
In the management of small-bowel angioectasia, type 1a
lesions without oozing do not require endoscopic treat-
ment. However type 1a angioectasias with oozing are indi-
cated for PDI, and type 1b angioectasias are indicated for
PDI combined with APC or clipping.
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